electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

electroCore (NASDAQ: ECOR) announced on October 3, 2025 that Jennifer Hayes will join the company as Vice President, Human Resources and Employee Success, effective October 6, 2025.

The Compensation Committee granted 10,000 restricted stock units (RSUs) as an inducement under NASDAQ Listing Rule 5635(c)(4). The RSUs vest one-third on each of the first, second and third anniversaries of the grant, subject to continued employment, and will be settled in shares of common stock upon vesting.

News Market Reaction

%

1 alert

% News Effect

On the day this news was published, ECOR declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, as the Company’s Vice President, Human Resources and Employee Success. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Ms. Hayes in connection with the commencement of her employment. The RSUs were granted as an inducement material to Ms. Hayes’ commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). One-third of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Ms. Hayes’ continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company’s common stock.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance. For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

FAQ

Who is joining electroCore (ECOR) and when does her employment start?

Jennifer Hayes will join as VP, Human Resources and Employee Success, effective October 6, 2025.

How many RSUs did electroCore grant to Jennifer Hayes under NASDAQ rule 5635(c)(4)?

The Compensation Committee granted 10,000 restricted stock units as an inducement award.

What is the vesting schedule for the 10,000 RSUs granted by electroCore (ECOR)?

One-third of the RSUs vest on each of the first, second and third anniversaries of the grant, subject to continued employment.

Will electroCore settle the RSUs in cash or shares when they vest?

Upon vesting, the RSUs will be settled in shares of electroCore common stock.

Under which Nasdaq rule was the inducement RSU grant to Jennifer Hayes made?

The grant was made pursuant to NASDAQ Listing Rule 5635(c)(4) as an inducement material to her commencement of employment.

Does the press release disclose any financial impact or dilution from the RSU grant to ECOR shareholders?

No. The release states the 10,000 RSU grant and vesting terms but does not quantify financial impact or dilution.